secwatch / observer
8-K filed May 15, 2024, 7:59 PM ET ticker XTNT CIK 0001453593
earnings confidence high sentiment positive materiality 0.75

Xtant Medical Q1 revenue up 55% to $27.9M; raises FY2024 revenue guidance to $116M-$120M

Xtant Medical Holdings, Inc.

2024-Q1 EPS reported -$0.03 revenue$27,873,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Xtant Medical Holdings, Inc. reported first quarter ended March 31, 2024 results: revenue $27.9 million, net income $4.3 million, or $0.03 per share, EPS $0.03 per share. Guidance raised.

Period
first quarter ended March 31, 2024
Revenue
$27.9 million
Net income
$4.3 million, or $0.03 per share
EPS
$0.03 per share
Guidance
raised
Result
reported results
Exact text from the filing
treatment of spinal disorders, today reported financial and operating results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights ● Revenue of $27.9 million, up 55%, compared to the prior year quarter ● Gross margin of 62.1%, up 340 basis points, compared to the prior year quarter ● Net loss of $4.4 million compared to $2.1 million
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Xtant Medical Holdings, Inc. reported full year 2024 results: revenue $116 million to $120 million. Guidance raised.

Period
full year 2024
Revenue
$116 million to $120 million
Guidance
raised
Result
guidance update
Exact text from the filing
Xtant Medical raises its expectation for full year 2024 revenue to $116 million to $120 million, up from the Company’s prior guidance of $112 million to $116 million.
View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Xtant Medical Holdings, Inc. filing history →

Source: SEC EDGAR
accession 0001493152-24-019864
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.